NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
Clinical Trials
209 trialsNCT04919382 2026-03-12
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05903092 2026-03-12
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT04516070 2026-03-05
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05068232 2026-03-04
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
University of Chicago
Phase 2 Recruiting
NCT07402343 2026-03-04
T-BRAIN
Maastricht University Medical Center
Phase 2 Not yet recruiting
NCT06719700 2026-03-03
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07149363 2026-02-17
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Recruiting
NCT05419076 2026-02-11
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07398560 2026-02-10
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
The Third Affiliated Hospital of Harbin Medical University
Phase 2 Not yet recruiting
NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
NCT07242547 2026-02-04
MERLIN
Fundación GECP
Phase 2 Recruiting
NCT07339059 2026-01-30
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07373964 2026-01-28
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
China Medical University, China
Phase 2 Recruiting
NCT07057791 2026-01-27
PrE0510
PrECOG, LLC.
Phase 2 Recruiting
NCT07357532 2026-01-22
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05450965 2025-12-17
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore
Phase 2 Recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06758700 2025-12-05
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT04010357 2025-12-02
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05588388 2025-11-17
BELIEVE
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT04397003 2025-10-22
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT04472949 2025-10-01
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT07200154 2025-09-30
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT07103408 2025-08-05
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07097948 2025-08-01
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT02769832 2025-07-29
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
University of Iowa
Phase 2 Completed
NCT07091305 2025-07-29
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT07076914 2025-07-22
PPI-PROTECT
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Not yet recruiting
NCT03670056 2025-07-20
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Yale University
Phase 2 Active not recruiting
NCT07055581 2025-07-09
Durvalumab as Consolidation for Patients LS-SCLC
Tongji Hospital
Phase 2 Not yet recruiting
NCT05578326 2025-07-08
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06227546 2025-07-08
MGC018-SCLC
Georgetown University
Phase 2 Active not recruiting
NCT05617963 2025-06-15
DURVALUNG
UNICANCER
Phase 2 Recruiting
NCT04952480 2025-06-12
DARTS
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT07004712 2025-06-08
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06424067 2025-05-25
Phase 2 Study of Fingolimod in Lung Cancers
Medical University of South Carolina
Phase 2 Recruiting
NCT06419179 2025-05-20
GUIDANCE
University of Cologne
Phase 2 Enrolling by invitation
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT06914050 2025-04-25
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting